Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo
{"title":"Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next-Generation PD-1 Immunotherapy","authors":"Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo","doi":"10.1002/cdt3.70017","DOIUrl":null,"url":null,"abstract":"<p>Tislelizumab is a next-generation PD-1 monoclonal antibody developed to overcome the limitations of earlier immune checkpoint inhibitors. By eliminating Fcγ receptor binding, it avoids macrophage-mediated T-cell clearance and enhances the antitumor immune response. Unlike conventional PD-1 inhibitors, tislelizumab binds to PD-1 in a way that more closely mimics the natural PD-L1 interaction, potentially improving efficacy and reducing immune-related toxicity. This review highlights its structural advantages, clinical efficacy across multiple cancers, and recent global regulatory approvals. We also discuss key pharmacokinetic features and current challenges, including the need for predictive biomarkers, immune-related adverse events, and combination therapy strategies. Together, these insights may guide the more effective and safer use of tislelizumab in cancer immunotherapy.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"173-185"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70017","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Diseases and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.70017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Tislelizumab is a next-generation PD-1 monoclonal antibody developed to overcome the limitations of earlier immune checkpoint inhibitors. By eliminating Fcγ receptor binding, it avoids macrophage-mediated T-cell clearance and enhances the antitumor immune response. Unlike conventional PD-1 inhibitors, tislelizumab binds to PD-1 in a way that more closely mimics the natural PD-L1 interaction, potentially improving efficacy and reducing immune-related toxicity. This review highlights its structural advantages, clinical efficacy across multiple cancers, and recent global regulatory approvals. We also discuss key pharmacokinetic features and current challenges, including the need for predictive biomarkers, immune-related adverse events, and combination therapy strategies. Together, these insights may guide the more effective and safer use of tislelizumab in cancer immunotherapy.
期刊介绍：
This journal aims to promote progress from basic research to clinical practice and to provide a forum for communication among basic, translational, and clinical research practitioners and physicians from all relevant disciplines. Chronic diseases such as cardiovascular diseases, cancer, diabetes, stroke, chronic respiratory diseases (such as asthma and COPD), chronic kidney diseases, and related translational research. Topics of interest for Chronic Diseases and Translational Medicine include Research and commentary on models of chronic diseases with significant implications for disease diagnosis and treatment Investigative studies of human biology with an emphasis on disease Perspectives and reviews on research topics that discuss the implications of findings from the viewpoints of basic science and clinical practic.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
